AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Jun 24, 2021
31637_dirs_2021-06-24_d3dbf7e6-47a6-405f-ab2c-0c6a700b592e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-06-23
Reporting Person: SATO VICKI L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-23 | Common Stock | S | 680 | $70.199 | Disposed | 135483 | Direct |
| 2021-06-23 | Common Stock | S | 986 | $71.105 | Disposed | 134497 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $69.74 to $70.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 2,074 restricted stock units.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $70.80 to $71.40 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.